| Sep 25 |
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
|
| Sep 4 |
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series
|
| Aug 19 |
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer
|
| Aug 14 |
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
|
| Jul 24 |
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
|
| Jun 20 |
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|
| Jun 20 |
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
|
| Jun 13 |
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
|
| May 28 |
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
|
| May 22 |
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
|
